Poster Presentation Joint 2016 COSA and ANZBCTG Annual Scientific Meeting

Assessing the impact of chemotherapy-induced peripheral neuropathy in Australia via a patient survey (#211)

Eva Battaglini 1 , David Goldstein 2 3 , Susanna B Park 4
  1. Prince of Wales Clinical School, University of New South Wales, Randwick, NSW, Australia
  2. Prince of Wales Clinical School, University of New South Wales, Randwick, NSW, Australia
  3. Medical Oncology, Prince of Wales Hospital, Randwick, NSW, Australia
  4. Brain and Mind Centre, University of Sydney, Sydney, NSW, Australia

Chemotherapy-induced peripheral neuropathy (CIPN) is a major side effect of cancer treatments, and can lead to long-term functional disability and reduced quality of life. Despite this, to date there has been a lack of large-scale studies into CIPN in Australia, and its impact is poorly understood. Our aim is to investigate the impact of neurotoxic chemotherapy side effects on the health, physical activity, and quality of life of Australian cancer survivors via an anonymous online survey. The survey addresses demographics, cancer diagnosis and treatment, information on the experience of CIPN and other side effects of chemotherapy, as well as including standardised measures to assess general health, quality of life, physical activity, CIPN symptoms and pain. The survey aims to recruit 2000 participants who have received neurotoxic chemotherapy. Recruitment will take place over a period of 2 years. Interim analysis of 305 respondents with a mean age of 58 ± 9.8 years indicates a greater prevalence of female responders (89.4% female, 10.6% male). Cancer types reported include primarily breast, colorectal and ovarian cancer, and chemotherapy types reported include carboplatin, paclitaxel, docetaxel and oxaliplatin, with 14% of participants unsure of the name of the chemotherapy that they had received. Of the cohort, 73% were currently experiencing neuropathic symptoms in the hands or feet. Respondents ranked neuropathy as the second most troubling side effect of cancer treatment after fatigue, with 15% of participants reporting neuropathy as having the biggest impact on their lives and 33% of participants reporting fatigue as having the biggest impact. These preliminary results support the importance of investigating this issue. This first large patient survey to specifically assess the impact of CIPN in Australia will provide important information on the impact of this debilitating condition.